Corcept Therapeutics (CORT)
Health Care · Specialty pharmaceuticals - endocrinology and oncology
Corcept develops selective cortisol modulators to treat Cushing's syndrome and cancer, combining an established endocrinology franchise with a newly approved oncology therapy.
What Corcept Therapeutics does
Corcept Therapeutics is a commercial-stage company focused on discovering and developing selective cortisol modulators to treat endocrinologic, oncologic, metabolic, and neurologic disorders. The company markets Korlym (mifepristone) and an authorized generic version in the United States for hypercortisolism (Cushing's syndrome), and in April 2026 began selling Lifyorli (relacorilant), its first oncology product approved by the FDA for platinum-resistant ovarian cancer in combination with chemotherapy. The company's portfolio includes over 1,000 proprietary cortisol modulator compounds designed to modulate cortisol effects without the progesterone-related adverse effects of mifepristone.
Themes: ["Cushing's syndrome / hypercortisolism treatment","Cortisol modulation / endocrinology","Oncology - ovarian cancer","Metabolic dysfunction-associated steatohepatitis (MASH)","Neurologic disorders (ALS)"]
Fundamentals
- Price$93.25 as of 2026-07-09 close
- Market cap$10.2B as of 2026-07-10
- 1-year return+31.5% as of 2026-07-09 close
- P/E214.78 as of 2026-07-10
- Net margin+6.2% as of 2026-07-10
- Gross margin+98.3% as of 2026-07-10
- ROE+7.4% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+12.2% as of 2026-07-10
- Revenue CAGR (3y)+23.7% SEC XBRL
- Beta0.49 as of 2026-07-10
Key risks (from latest filing)
["Product portfolio concentration risk: The company currently derives revenue from two medications (Korlym and Lifyorli); loss or diminished uptake of either could materially impact financial performance.","Regulatory and clinical trial execution risk: Multiple lead compounds are in clinical development for serious indications; failure to meet endpoints or obtain regulatory approval could limit revenue growth and require significant R&D capital reallocation.","Specialty pharmacy transition risk: The company recently transitioned specialty pharmacy operations from Optime to Curant Health; disruption in distribution or patient support services could affect drug accessibility and sales."]
Competitors & peers
- Novartis (NVS) - wide range of endocrine and oncology treatments
- Pfizer (PFE) - oncology and endocrinology portfolio
- Merck (MRK) - oncology therapies including immunotherapies
- Bristol Myers Squibb (BMY) - oncology and specialty care
- AstraZeneca (AZN) - oncology treatments for ovarian cancer
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.